Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Utility of multigene panel next-generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer.
Nindra U, Pal A, Bray V, Yip PY, Tognela A, Roberts TL, Becker TM, Williamson J, Farzin M, Li JJ, Lea V, Hagelamin A, Ng W, Wang B, Lee CS, Chua W. Nindra U, et al. Among authors: yip py. Intern Med J. 2024 Apr;54(4):596-601. doi: 10.1111/imj.16224. Epub 2023 Sep 15. Intern Med J. 2024. PMID: 37713593
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Selinger CI, Li BT, Pavlakis N, Links M, Gill AJ, Lee A, Clarke S, Tran TN, Lum T, Yip PY, Horvath L, Yu B, Kohonen-Corish MR, O'Toole SA, Cooper WA. Selinger CI, et al. Among authors: yip py. Histopathology. 2017 Feb;70(3):402-411. doi: 10.1111/his.13076. Epub 2016 Nov 15. Histopathology. 2017. PMID: 27599111 Free PMC article.
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance.
Itchins M, Liang S, Brown C, Barnes T, Marx G, Chin V, Kao S, Yip PY, Mersiades AJ, Nagrial A, Bray V, Peters G, Parakh S, Garg K, Li BT, McKay M, O'Byrne K, John T, Gill AJ, Molloy MP, Solomon BJ, Pavlakis N. Itchins M, et al. Among authors: yip py. JTO Clin Res Rep. 2024 Jul 8;5(9):100703. doi: 10.1016/j.jtocrr.2024.100703. eCollection 2024 Sep. JTO Clin Res Rep. 2024. PMID: 39309618 Free PMC article.
Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer.
Stevens S, Nindra U, Shahnam A, Wei J, Bray V, Pal A, Yip PY, Linton A, Blinman P, Nagrial A, Lee J, Boyer M, Kao S. Stevens S, et al. Among authors: yip py. J Geriatr Oncol. 2024 Mar;15(2):101705. doi: 10.1016/j.jgo.2024.101705. Epub 2024 Jan 29. J Geriatr Oncol. 2024. PMID: 38290173 Free article.
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
McNamee N, Harvey C, Gray L, Khoo T, Lingam L, Zhang B, Nindra U, Yip PY, Pal A, Clay T, Arulananda S, Itchins M, Pavlakis N, Kao S, Bowyer S, Chin V, Warburton L, Pires da Silva I, John T, Solomon B, Alexander M, Nagrial A. McNamee N, et al. Among authors: yip py. J Thorac Oncol. 2024 Apr;19(4):636-642. doi: 10.1016/j.jtho.2023.11.014. Epub 2023 Nov 28. J Thorac Oncol. 2024. PMID: 38036250
23 results